文献速递垂体与肾上腺疾病

先天性肾上腺增生症儿科患者氢化可的松治疗的药代动力学/药效学评价

Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本研究利用30例7-17岁先天性肾上腺增生症(CAH)患者的皮质醇和17-羟孕酮(17-OHP)浓度建立药代动力学/药效学(PK/PD)模型,评估不同氢化可的松给药方案。模型显示皮质醇生物利用度为82.6%,抑制50% 17-OHP合成的皮质醇浓度为48.6 nmol/L。模拟表明每日4次给药比每日3次给药更能达到目标范围并模拟皮质醇昼夜节律,作者建议每日剂量分配为06:00给38%、12:00给22%、18:00给17%、24:00给22%。

要点

  • 研究建立了一个以17-OHP为生物标志物的氢化可的松PK/PD模型,皮质醇生物利用度为82.6%。
  • 抑制50% 17-OHP合成的皮质醇浓度为48.6 nmol/L。
  • 模拟显示每日4次给药比每日3次给药更能达到目标范围并避免亚治疗浓度。

核心结论

  • 作者建议的氢化可的松每日剂量分配为06:00给38%、12:00给22%、18:00给17%、24:00给22%。
  • 每日4次给药方案优于每日3次给药,可避免亚治疗皮质醇浓度并更好地模拟皮质醇昼夜节律。

研究设计与样本

  • 研究纳入30例7-17岁接受标准氢化可的松替代治疗(5-20 mg)的CAH患者,其中每日2次给药17例、每日3次给药13例,利用其皮质醇和17-OHP浓度数据建立PK/PD模型。
  • 随后模拟临床相关的每日3次和每日4次给药方案的皮质醇浓度,并与皮质醇和17-OHP目标范围及健康儿童浓度进行比较。

主要发现

  • 皮质醇浓度-时间曲线由具有一级吸收和预期高生物利用度(82.6%)的二室模型准确描述。
  • 具有时间延迟和皮质醇介导的17-OHP合成抑制的模型准确描述了17-OHP浓度。
  • 抑制50% 17-OHP合成的皮质醇浓度为48.6 nmol/L。
  • 模拟显示每日4次给药比每日3次给药更好地达到目标范围,并在24小时期间模拟皮质醇浓度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with congenital adrenal hyperplasia (CAH) require lifelong replacement therapy with glucocorticoids. Optimizing hydrocortisone therapy is challenging, since there are no established cortisol concentration targets other than the cortisol circadian rhythm profile. 17-hydroxyprogesterone (17-OHP) concentrations are elevated in these patients and commonly used to monitor therapy. This study aimed to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of cortisol using 17-OHP as a biomarker in pediatric patients with CAH and to assess different hydrocortisone dosing regimens. METHODS: Cortisol and 17-OHP concentrations from 30 CAH patients (7-17 years of age) receiving standard hydrocortisone replacement therapy (5-20 mg) twice (n = 17) or 3 times (n = 13) daily were used to develop a PK/PD model. Sequentially, simulated cortisol concentrations for clinically relevant 3- and 4-times daily dosing regimens were compared with cortisol and 17-OHP target ranges and to concentrations in healthy children. RESULTS: Cortisol concentration-time profiles were accurately described by a 2-compartment model with first-order absorption and expected high bioavailability (82.6%). A time-delayed model with cortisol-mediated inhibition of 17-OHP synthesis accurately described 17-OHP concentrations. The cortisol concentration inhibiting 50% of 17-OHP synthesis was 48.6 nmol/L. A 4-times-daily dosing better attained the target ranges and mimicked the cortisol concentrations throughout the 24-hour period than 3-times-daily. CONCLUSIONS: A PK/PD model following hydrocortisone administration has been established. An improved dosing regimen of 38% at 06:00, 22% at 12:00, 17% at 18:00, and 22% at 24:00 of the daily hydrocortisone dose was suggested. The 4-times-daily dosing regimen was superior, avoiding subtherapeutic cortisol concentrations and better resembling the circadian rhythm of cortisol.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Melin J, Parra-Guillen ZP, Michelet R, et al. Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2020. PMID: 32052005. doi:10.1210/clinem/dgaa071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。